Ann Boriack-Sjodin

Ann Boriack-Sjodin

Company: Accent Therapeutics

Job title: Vice President, Molecular Discovery


RMP-Targeted Cancer Drug Discovery 3:30 pm

RNA modifying proteins (RMPs) represent a large class of novel targets for oncology and other disease indications that can be targeted with small molecule inhibitors The enzyme ADAR1 (Adenosine Deaminases Acting on RNA) catalyzes the majority of A-to-I editing, where it has been demonstrated to effect coding sequence, miRNA function and the detection of repetitive…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.